Mometasone Teva (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This suppresses the production of inflammatory mediators, reduces leukocyte infiltration, and limits edema, providing potent anti‑inflammatory and immunosuppressive effects at the site of application.

The specific dosage and frequency are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated, and patient age. Patients should follow the exact instructions provided on the prescription label.

Safety data for topical mometasone during pregnancy and lactation are limited. Healthcare providers usually weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is classified as a high‑potency topical corticosteroid, offering stronger anti‑inflammatory action than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol, mometasone may have a slightly lower risk of skin atrophy when used as directed, but clinical choice depends on the specific condition and physician preference.

Store the cream below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Ensure the container is tightly closed to maintain product stability. Do not freeze the product, and keep it out of reach of children.

Apply a thin layer of the cream to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until fully absorbed, and wash hands after application unless treating the hands themselves. Avoid contact with eyes, mouth and open wounds unless instructed.

Serious risks include skin atrophy, secondary infections, systemic adrenal suppression, and rare systemic Cushingoid effects when used over large areas or for prolonged periods. Patients should report signs of thinning skin, unusual bruising, severe fatigue, or hormonal disturbances to their healthcare provider promptly.

Mometasone Teva should be avoided in individuals with known hypersensitivity to mometasone furoate or any cream excipients, and it is contraindicated on skin infected with untreated bacterial, viral, or fungal organisms. Patients with uncontrolled systemic infections or those receiving systemic corticosteroids without medical supervision should also refrain from use.